Search results
Showing 631 to 645 of 654 results for kidney or kidneys or renal
The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
with acute or chronic severe sciatica. Cash savings: £2,000 Guideline on renal and ureteric stones: assessment and management (NG118)...
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.
This indicator covers those patients aged between 25 and 84 years, with a new diagnosis of hypertension or type 2 diabetes recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes), who have a recorded cardiovascular risk assessment score of 10% or more in the preceding 12 months: the percentage who are currently treated with a lipid lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: assessment of stroke/VTE risk; assessment of bleeding risk; assessment of renal function, creatinine clearance, FBC and LFTs as appropriate for their anticoagulation therapy; any adverse effects related to anticoagulation; assessment of compliance; choice of anticoagulant. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM147
Improvements for people with acute kidney injury in updated quality standard
An updated quality standard published today (23 March 2023) by NICE outlines improvements in care for people who have or are at risk of acute kidney injury.
Four innovative tests for diagnosing UTIs could help in the fight against antimicrobial resistance
NHS may use innovative tests which may help people with a urinary tract infection (UTI) receive the correct course of antibiotics more quickly.
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance.
This indicator covers the percentage of patients aged between 25 and 84 years with a new diagnosis of hypertension or type 2 diabetes, recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a consultation for full formal cardiovascular disease risk assessment between 3 months before or 3 months after date of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM132
This indicator covers the percentage of patients aged between 25 and 84 years with schizophrenia, bipolar affective disorder and other psychoses (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a full formal cardiovascular disease risk assessment performed in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM120
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.